Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 59.7%

Neg 59.7% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $58 to $28.